Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 30;14(3):2066-2077.
doi: 10.21037/tcr-2025-485. Epub 2025 Mar 27.

Diagnostic test of conventional ultrasonography combined with contrast-enhanced ultrasound in the subcategorization of suspicious Breast Imaging-Reporting and Data System (BI-RADS) 4 breast lesions

Affiliations

Diagnostic test of conventional ultrasonography combined with contrast-enhanced ultrasound in the subcategorization of suspicious Breast Imaging-Reporting and Data System (BI-RADS) 4 breast lesions

Yindi Zhu et al. Transl Cancer Res. .

Abstract

Background: Although conventional ultrasonography (CUS) and contrast-enhanced ultrasound (CEUS) play a critical role in cancer detection, diagnosis, and image-guided biopsies, there is no standardized diagnostic approach for the clinical evaluation of suspected Breast Imaging-Reporting and Data System (BI-RADS) category 4 breast lesions. This diagnostic test evaluates the complementary roles of CUS and CEUS in addressing limitations of conventional imaging, such as microvascular visualization. This study aimed to evaluate the diagnostic value of combining CUS with CEUS in subcategorizing suspicious breast lesions classified as BI-RADS for ultrasound (US-BI-RADS) category 4.

Methods: The data of 131 patients with BI-RADS category 4 breast lesions, examined between February 2017 and March 2023, were retrospectively analyzed. All lesions underwent pathological examination following surgery and served as the gold standard for diagnosis. Key features such as lesion margins, echogenicity, size, microcalcification, blood flow distribution via color Doppler flow imaging (CDFI), and CEUS characteristics were assessed. CEUS scores were calculated using a five-point scoring system. Stepwise logistic regression was applied to evaluate the odds ratios (ORs) of the lesion characteristics on US and CEUS. The combination of the US-BI-RADS and CEUS scores (termed the CEUS-BI-RADS) was compared to the US-BI-RADS alone, and a receiver operating characteristic (ROC) curve analysis was conducted to determine the diagnostic performance of these methods.

Results: Of the 131 lesions, 62 (47.3%) were benign, and 69 (52.7%) were malignant. The multivariate logistic regression identified the primary indicators of malignancy as calcification [OR =1.58, 95% confidence interval (CI): 0.25-2.91, P=0.02], suspicious or abnormal axillary lymph nodes (OR =2.51, 95% CI: 0.59-4.44, P=0.01), obscure margins after enhancement (OR =2.67, 95% CI: 0.35 to 4.99, P=0.02), and increased lesion size (OR =4.89, 95% CI: 1.45-8.33, P=0.005). The sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of the US-BI-RADS were 73.9%, 74.2%, 74.0%, 71.9%, and 76.1%, respectively, while those of the CEUS-BI-RADS were 92.8%, 79.0%, 86.3%, 90.7%, and 83.1%, respectively. The areas under the ROC curves for the US-BI-RADS and CEUS-BI-RADS were 0.741 and 0.859, respectively.

Conclusions: The CEUS-BI-RADS significantly enhances diagnostic efficacy for BI-RADS category 4 breast lesions, outperforming the US-BI-RADS and could reduce unnecessary biopsies.

Keywords: Breast Imaging-Reporting and Data System category 4 (BI-RADS 4); Conventional ultrasonography (CUS); breast cancer (BC); contrast-enhanced ultrasound (CEUS); diagnosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-485/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
US and CEUS images of a 51-year-old female diagnosed with fibrocystic breast disease at histopathology. (A) Gray-scale US image showing low echo and unclear boundaries in the left breast. Asterisks indicate the borders of the nodules. (B) Color Doppler US showing abundant blood vessels in the lesion. The lesion was diagnosed as BI-RADS 4B on US. (C) CEUS image showing no enlargement of the lesion, clear boundaries, regular morphology, and no crab claw-like sign, which were diagnosed as benign features on CEUS. (D) Histopathological analysis revealed fibrocystic breast disease (hematoxylin and eosin staining; original magnification, ×100). BI-RADS, Breast Imaging-Reporting and Data System; CEUS, contrast-enhanced ultrasound; US, ultrasonography.
Figure 2
Figure 2
Multivariate logistic regression analysis results of benign and malignant breast lesions. CI, confidence interval; OR, odds ratio.
Figure 3
Figure 3
ROC curves of diagnostic efficacy for the US-BI-RADS and the CEUS-BI-RADS. BI-RADS, Breast Imaging-Reporting and Data System; CEUS, contrast-enhanced ultrasound; CEUS-BI-RADS, the combination of US-BI-RADS and CEUS scores; ROC, receiver operating characteristic; US, ultrasonography; US-BI-RADS, BI-RADS for ultrasound.

Similar articles

References

    1. Franklin M, Pollard D, Sah J, et al. Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review. Adv Ther 2024;41:2700-22. 10.1007/s12325-024-02893-y - DOI - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660 - DOI - PubMed
    1. Daly C, Puckett Y. New Breast Mass. In StatPearls. StatPearls Publishing; 2022.
    1. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine (Baltimore) 2024;103:e36905. 10.1097/MD.0000000000036905 - DOI - PMC - PubMed
    1. Spear G, Lee K, DePersia A, et al. Updates in Breast Cancer Screening and Diagnosis. Curr Treat Options Oncol 2024;25:1451-60. 10.1007/s11864-024-01271-8 - DOI - PubMed

LinkOut - more resources